Microbiome in Cancer Development and Treatment DOI Creative Commons
Soňa Čierniková, Aneta Sevcikova,

Beáta Mladosievičová

et al.

Microorganisms, Journal Year: 2023, Volume and Issue: 12(1), P. 24 - 24

Published: Dec. 22, 2023

Targeting the microbiome, microbiota-derived metabolites, and related pathways represents a significant challenge in oncology. Microbiome analyses have confirmed negative impact of cancer treatment on gut homeostasis, resulting acute dysbiosis severe complications, including massive inflammatory immune response, mucosal barrier disruption, bacterial translocation across epithelium. Moreover, recent studies revealed relationship between an imbalance microbiome treatment-related toxicity. In this review, we provide current insights into role tumor development microbiomes chemo- immunotherapy efficacy, as well treatment-induced late effects, cognitive impairment cardiotoxicity. As discussed, microbiota modulation via probiotic supplementation fecal transplantation new trend patient care, aiming to increase diversity, alleviate long-term toxicity, improve response various modalities. However, more detailed understanding complex host can significantly contribute integrating microbiome-based approach clinical practice. Determination causal correlations might lead identification clinically relevant diagnostic prognostic microbial biomarkers. Notably, restoration intestinal homeostasis could optimizing efficacy improving outcomes.

Language: Английский

Sex differences in colorectal cancer: with a focus on sex hormone–gut microbiome axis DOI Creative Commons
Zihong Wu, Yuqing Huang, Renyi Zhang

et al.

Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)

Published: March 7, 2024

Abstract Sexual dimorphism has been observed in the incidence and prognosis of colorectal cancer (CRC), with men generally exhibiting a slightly higher than women. Research suggests that this difference may be attributed to variations sex steroid hormone levels gut microbiome. The microbiome CRC shows composition function between sexes, leading concept ‘microgenderome’ ‘sex hormone–gut axis.’ Conventional research indicates estrogens, by promoting more favorable microbiota, reduce risk CRC. Conversely, androgens have direct pro-tumorigenic effect increasing proportion opportunistic pathogens. microbiota also influence expressing specific enzymes or directly affecting gonadal function. However, area remains controversial. This review aims explore differences incidence, phenomenon sexual within microbiome, intricate interplay axis objective is gain better understanding these interactions their potential clinical implications, as well introduce innovative approaches treatment. Graphical

Language: Английский

Citations

19
Exploring probiotics as a sustainable alternative to antimicrobial growth promoters: mechanisms and benefits in animal health DOI Creative Commons

Angel Sachdeva,

Tanu Tomar,

Tabarak Malik

et al.

Frontiers in Sustainable Food Systems, Journal Year: 2025, Volume and Issue: 8

Published: Jan. 3, 2025

The extensive use of antimicrobial growth promoters (AGPs) in livestock has raised global concerns due to increasing resistance (AMR) among pathogenic microbes. This review examines probiotics as a sustainable alternative AGPs, offering safer approach for promoting animal and health. Probiotics enhance productivity immunity by producing compounds competing with pathogens nutrients. In addition, strengthen the gut barrier modulate microbiome, facilitating beneficial bacterial while suppressing species. Studies demonstrate efficacy probiotic strains genera Lactobacillus Bifidobacterium inhibiting such Clostridium perfringens Salmonella livestock. comprehensive evaluation highlights probiotics' potential advance practices, reduce reliance on antibiotics, mitigate AMR risks, underscoring need further research regulatory considerations their husbandry.

Language: Английский

Citations

2
Modulating the gut microbiota by probiotics, prebiotics, postbiotics, and fecal microbiota transplantation: An emerging trend in cancer patient care DOI Open Access
Soňa Čierniková, Aneta Sevcikova, Ľuboš Drgoňa

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2023, Volume and Issue: 1878(6), P. 188990 - 188990

Published: Sept. 23, 2023

Language: Английский

Citations

23
Current Advances of Nanomaterial-Based Oral Drug Delivery for Colorectal Cancer Treatment DOI Creative Commons

Nuoya Wang,

Liqing Chen, Wei Huang

et al.

Nanomaterials, Journal Year: 2024, Volume and Issue: 14(7), P. 557 - 557

Published: March 22, 2024

Colorectal cancer (CRC) is a common malignant tumor, and traditional treatments include surgical resection radiotherapy. However, local recurrence, distal metastasis, intestinal obstruction are significant problems. Oral nano-formulation promising treatment strategy for CRC. This study introduces physiological environmental factors, the main challenges of CRC treatment, need novel oral colon-targeted drug delivery system (OCDDS). reviews research progress controlled-release, responsive, magnetic, targeted, other nano-formulations in direction addition to advantages concerns about related therapeutic agents inspire research.

Language: Английский

Citations

13
Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy DOI Creative Commons
Yufei Deng, Xiaoying Hou,

Haiping Wang

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(5), P. 604 - 604

Published: May 8, 2024

The involvement of the gut microbiota in anti-cancer treatment has gained increasing attention. Alterations to structure and function bacteria are important factors development cancer as well efficacy chemotherapy. Recent studies have confirmed that related metabolites influence pharmacological activity chemotherapeutic agents through interactions with immune system. This review aims summarize current knowledge how malignant tumor chemotherapy affect microbiota, regulates host response, between response advances strategies for efficiency based on also described. Deciphering complex homeostasis maintained by immunity provides a solid scientific basis bacterial intervention

Language: Английский

Citations

9
Microbiome and pancreatic cancer: time to think about chemotherapy DOI Creative Commons
Juliana de Castilhos,

Katharina Tillmanns,

J. A. BLESSING

et al.

Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)

Published: July 18, 2024

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer characterized by late diagnosis, rapid progression, and high mortality rate. Its complex biology, dense, stromal tumor environment with an immunosuppressive milieu, contributes to resistance against standard treatments like chemotherapy radiation. This comprehensive review explores the dynamic role of microbiome in modulating efficacy outcomes PDAC. It delves into microbiome's impact on drug metabolism resistance, interaction between microbial elements, drugs, human biology. We also highlight significance specific bacterial species enzymes influencing action immune response microenvironment. Cutting-edge methodologies, including artificial intelligence, low-biomass analysis patient-derived organoid models, are discussed, offering insights nuanced interactions microbes cells. The potential microbiome-based interventions as adjuncts conventional PDAC paving way for personalized therapy approaches. synthesizes recent research provide in-depth understanding how affects efficacy. focuses elucidating key mechanisms identifying existing knowledge gaps. Addressing these gaps crucial enhancing medicine refining treatment strategies, ultimately improving patient outcomes.

Language: Английский

Citations

9
Oral probiotic supplementation to alleviate diarrhea induced by fluoropyrimidines or irinotecan-based chemotherapy: a systematic review and meta-analysis DOI Creative Commons
Tippawan Siritientong, Daylia Thet, Nattawut Leelakanok

et al.

Complementary Therapies in Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 103151 - 103151

Published: Feb. 1, 2025

Fluoropyrimidines and irinotecan cause diarrhea, which can be particularly severe in some cases. Probiotic supplementation is a potential option for managing chemotherapy-induced diarrhea. This study aims to evaluate the efficacy safety of probiotics diarrhea induced by fluoropyrimidine or irinotecan-based chemotherapy cancer patients. A literature search was conducted Cochrane Library, PubMed, ScienceDirect, SciFinder, Scopus August 2023. Observational prospective studies patients receiving 5-fluorouracil, capecitabine, were included. RevMan (version 5.4.1) used statistical analysis. The protocol registered PROSPERO. Of 9400 records, 24 14 included systematic review meta-analysis, respectively. Most provided combination probiotic strains from initiation completion cycles. significantly reduced all grade (RR = 0.40; 95% CI: 0.27, 0.60; P < 0.00001, I2: 0%), nausea vomiting 0.49; CI [0.37, 0.67]; bloating 0.27; [0.11, 0.69]; 0.006, 0%) anorexia 0.62: [0.43, 0.90]; 0.01, 39%) compared controls. Absolute risk reductions (ARR) ranged 22.7% 28.5%, with number needed treat (NNT) value 3 5. Moreover, improved intestinal microbial balance symptom scales quality life. promising manage chemoradiotherapy-induced without serious side effects fluoropyrimidines regimens. Given clinically meaningful ARR favorable NNT values, may have role clinical practice. However, larger trials are standardize strain, dosage, duration, target patient subgroups. PROSPERO database (CRD42023473324).

Language: Английский

Citations

1
Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation DOI Creative Commons
Jiaao Sun,

Shiyan Song,

Jiahua Liu

et al.

npj Biofilms and Microbiomes, Journal Year: 2025, Volume and Issue: 11(1)

Published: March 11, 2025

In order to decipher the relationship between gut microbiota imbalance and cancer, this paper reviewed role of intestinal in anticancer therapy related mechanisms, discussed current research status as a biomarker finally summarized reasonable means regulating assist cancer therapy. Overall, our study reveals that can serve potential target for improving management.

Language: Английский

Citations

1
Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy DOI Creative Commons
Vicky Yao,

Nairui Fan,

Shuxia Ma

et al.

MedComm, Journal Year: 2025, Volume and Issue: 6(5)

Published: April 18, 2025

ABSTRACT Dysbiosis refers to the disruption of gut microbiota balance and is pathological basis various diseases. The main pathogenic mechanisms include impaired intestinal mucosal barrier function, inflammation activation, immune dysregulation, metabolic abnormalities. These involve dysfunctions in gut–brain axis, gut–liver others cause broader effects. Although association between diseases caused by dysbiosis has been extensively studied, many questions remain regarding specific treatment strategies. This review begins examining causes summarizes potential representative imbalance. It integrates clinical evidence explore preventive therapeutic strategies targeting emphasizing importance understanding dysbiosis. Finally, we summarized development artificial intelligence (AI) research suggested that it will play a critical role future studies on combining multiomics technologies AI further uncover complex drive personalized

Language: Английский

Citations

1
Black chokeberry (Aronia melanocarpa L.) polyphenols attenuate obesity-induced colonic inflammation by regulating gut microbiota and the TLR4/NF-κB signaling pathway in high fat diet-fed rats DOI
Yue Zhu,

Peng-ju Cai,

Han-chu Dai

et al.

Food & Function, Journal Year: 2023, Volume and Issue: 14(22), P. 10014 - 10030

Published: Jan. 1, 2023

This study investigated the potential benefits of black chokeberry polyphenol (BCP) supplementation on lipopolysaccharide (LPS)-stimulated inflammatory response in RAW264.7 cells and obesity-induced colonic inflammation a high fat diet (HFD)-fed rat model. Our findings demonstrated that BCP treatment effectively reduced production nitric oxide (NO) pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, MCP-1) LPS-induced concurrently mitigated oxidative stress by modulating levels malondialdehyde (MDA), catalase (CAT), glutathione peroxidase (GSH-Px) dose-dependent manner. Furthermore, significantly ameliorated HFD-induced obesity, improved glucose tolerance, systemic HFD-fed rats. Notably, suppressed mRNA expression alleviated intestinal barrier dysfunction regulating protein key tight junction proteins (ZO-1, occludin, claudin-1), thereby inhibiting caused TLR4/NF-κB signaling pathway. Additionally, altered composition function gut microbiota, leading to an increase total content short-chain fatty acids (SCFAs), particularly acetic acid, propionic isobutyric butyric acid. Collectively, our results highlighted as promising prebiotic strategy for treating inflammation.

Language: Английский

Citations

17